Company news
Egetis Therapeutics Ab (OMXSTO:EGTX) news
Egetis Therapeutics Ab news releases on 6ix. Latest, Sep 29, 2026: Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients…
Press releases & updates
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE(R) (tiratricol) for Patients with MCT8 Deficiency
September 29, 2026
Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 Deficiency
September 28, 2026
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
September 3, 2026
Egetis' Interim report Q2 2026
August 21, 2026
Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026
August 7, 2026
Change in the number of shares and votes in Egetis Therapeutics
May 29, 2026
Exercise of options under employee stock option program and notification of insider trading
May 13, 2026
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.
May 5, 2026
Egetis Therapeutics : Interim ReportQ12026
May 3, 2026
Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026
April 24, 2026
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million)
April 21, 2026
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million)
April 21, 2026
Egetis Appoints Tiago Nunes as Chief Medical Officer
April 9, 2026
Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate®
April 8, 2026
Egetis Therapeutics : – Corporate Presentation April 2026
April 7, 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency
March 27, 2026
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.
March 9, 2026
Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers
March 2, 2026